J. van den Bosch
Albert Schweitzer Hospital(GA)Albert Schweitzer Ziekenhuis(NL)
Publications by Year
Research Areas
Cancer Treatment and Pharmacology, Breast Cancer Treatment Studies, HER2/EGFR in Cancer Research, Estrogen and related hormone effects, Erythropoietin and Anemia Treatment
Most-Cited Works
- → Abstract S1-04: Optimal duration of extended letrozole treatment after 5 years of adjuvant endocrine therapy; results of the randomized phase III IDEAL trial (BOOG 2006-05)(2017)20 cited
- → Optimal duration of extended letrozole treatment after 5 years of adjuvant endocrine therapy; results of the randomized phase III IDEAL trial (BOOG 2006–05)(2017)12 cited
- → Quantification of outpatient management and hospitalization of patients with high-risk myelodysplastic syndrome treated with low-dose decitabine(2005)9 cited
- → Results of the Dutch scalp cooling registry in 7424 patients: analysis of determinants for scalp cooling efficacy(2024)5 cited
- → Plasma VEGF-a, angiopoietin-2 (ANG2) and soluble(s)TIE2 in patients (pts) with HER2-negative locally recurrent or metastatic breast cancer (LR/MBC) treated with first-line bevacizumab (A) and paclitaxel (T) without or with capecitabine (X).(2013)3 cited
- → Interim Results of BACH: Randomized Phase II Trial Evaluating the Safety of Two Chemotherapy Regimens as Adjuvant Therapy in Patients with HER2-Positive Breast Cancer: PLD + Cyclophosphamide + Trastuzumab (PLD+C+H), or Doxorubicin + Cyclophosphomide (A+C), Each Followed by Paclitaxel + Trastuzumab (T+H).(2009)2 cited
- → BACH: A randomized phase II trial of doxorubicin-cyclophosphamide (AC) versus pegylated liposomal doxorubicin (PLD)-cyclophosphamide-trastuzumab (CCH) followed by paclitaxel-trastuzumab (TH) as adjuvant therapy for HER2-positive breast cancer (BC)—Cardiac safety analysis.(2010)2 cited
- → Phase II study of paclitaxel (taxol, gemcitabine, and cisplatin for patients with advanced ovarian cancer)(2001)2 cited
- Completion pneumonectomy after bronchial sleeve resection(1992)
- Mr imaging as an additional s creening Modality for the Detection of Breast cancer in Women aged 50-75 Years with extremely Dense Breasts: The(2015)